drugset / Trial / NCT06784336

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT06784336

Phase 2 Recruiting 50 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.

Timeline

Start
2025-10-15
Primary completion
2028-10
Completion
2029-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferasirox Unknown 7 mg/kg
Subject Deferasirox Unknown 10 mg/kg
Subject Potato Resistant Starch Other / unclassified 20 g